

# Fundamental Relationships in Toxicology

M1 – Methods in Toxicology









#### **1. General principles of drug action**

- Affinity, Efficacy, Potency of drugs
- Dose-response-curves
- Types of agonists/antagonists
- Therapeutic index


#### 2. Targets of drugs

Receptors, enzymes, ion-channels, transporters





- Affinity: ability of the toxicant to bind to its receptor
- <u>Efficacy</u>: ability of a toxicant to evoke a cellular response




https://www.slideshare.net/PharmacologyEducationProject/introductory-receptor-pharmacology201415 jap to the standard s

- Agonist: high affinity and intrinsic activity/efficacy
- Antagonist: certain affinity but no intrinsic activity/efficacy








occupancy/affinity:
 K<sub>d</sub>: concentration, at which
 50% of receptors are
 occupied

— response/potency:
EC<sub>50</sub>: concentration, that causes 50% of the maximal effect

https://accesspharmacy.mhmedical.com/content.aspx?sectionid=95700976&bookid=1568





http://tmedweb.tulane.edu/pharmwiki/doku.php/basic\_principles\_of\_pharm


- Potency: refers to the amount of drug needed to produce a given effect  $\rightarrow EC_{50}$
- Efficacy: determines the maximum effect that a drug can produce regardless of dose  $\rightarrow E_{max}$



## **Types of Agonists**



- Full agonist: activate the receptor with a maximum response (e.g. morphine)
- Partial agonist: have only partial efficacy at the receptor relative to a full agonist (e.g. buprenorphine)



Agnostic about in Vivo Inverse Agonism of Agouti-Related Peptide, Malcolm J.


- Neutral Antagonist: intrinsic/basal level of activity in absence of any ligand
- Inverse agonist: decreases the activity below basal level (e.g. rimonabant)



### **Types of Antagonists**



Effect (%)



#### Competitive antagonist:


bind to receptor at the same binding site as the agonist but without activating it

 $EC_{50}$   $E_{max} = const.$ 



#### Non-competitive antagonists:

1. bind irreversibly to the same site as the agonist 2. allosteric modulation: bind to a different site as the agonist  $\rightarrow$  change in the binding affinity of the ligand (enhanced or decreased)




http://tmedweb.tulane.edu/pharmwiki/doku.php/basic\_principles\_of\_pharm

 $EC_{50} = const. E_{max} \downarrow$ 











https://www.sigmaaldrich.com/technical-documents/protocols/biology/transcreener-residence-time-protocol.html

 IC<sub>50</sub> value: concentration of antagonist, that is required for 50% inhibition of receptor or enzyme





https://psychopharmacologyinstitute.com/clinical-psychiatry/substance-use-disorders/buprenorphine-opioid-use-disorder-mechanism-action/




- http://tmedweb.tulane.edu/pharmwiki/doku.php/basic\_principles\_of\_pharm
- Toxic response curve: TD<sub>50</sub> = dose producing death in 50 % of cases
- Therapeutic Index: measure of drug safety

 $TI = \frac{Median \ toxic \ dose}{Median \ effective \ dose} = \frac{TD_{50}}{ED_{50}}$ 






http://pharmrev.aspetjournals.org/content/57/4/387



https://courses.washington.edu/conj/bess/transport/su mmary/NaKpump.png






Barbara Spix






- coupled directly to an ion channel
- crucially important for synaptic transmission in the CNS
- e.g. nicotinic Ach-receptor
- toxin:  $\alpha$ -Bungarotoxin





https://www.hongkongsnakeid.com/ma ny-banded-krait




http://www.tomhsiung.com/wordpress/2014/12/ligand-andvoltage-gated-channels-receptors/

http://jpet.aspetjournals.org/content/296/2/260





- site of action of about 45% of drugs
- coupled to intracellular effector mechanism via G-proteins → enzyme activation or opening of ion channel
- e.g. muscarinic Ach-receptor
- ligand: atropine



Competitive antagonist: Key effectors (examples): MAP kinases M current

Extracellular

M. M. M

Acetylcholine

M. M.

http://flipper.diff.org/app/pathways/1995

JAdenylyl cyclase

**TMAP** kinases

**TGIRK** channels

↓Voltage-operated Ca<sup>2+</sup> channels

https://www2.courses.vcu.edu/ptxed/m2/powerpoint/download/Damaj%20DR%20 Curves.PDF


Barbara Spix






- linked directly to an intracellular protein kinase that triggers a cascade of phosphorylation reactions
- receptor for cytokines, growth factors and hormones
- e.g. growth factor receptor
- ligand: dasatinib

Dasatinib is more potent in terms of IL-10 production











- intracellular receptors
- act as transcription factors that promote or inhibit synthesis of new proteins
- e.g. oestrogen receptor
- Ligand: tamoxifen





 $\label{eq:https://www.quora.com/Are-nuclear-receptors-attached-to-DNA-or-to-the-nuclear-membrane$ 



Enzymes




- site of action of about 30% of drugs
- inhibition of the active site may be competitive or long lasting and irreversible

Malathion-oxon:


lowest IC<sub>50</sub>  $\rightarrow$ 

highest potency

- e.g. acetylcholinesterase
- toxicant: organophosphates



 $https://www.researchgate.net/figure/The-concentration-dependent-inhibition-of-rat-brain-AChE-by-the-OP-pesticides_fig4_8369600$ 



http://www.u-helmich.de/bio/lexikon/A/acetylcholinesterase.html






- ion channels that are activated by changes in the electrical membrane potential near the channel
- found in excitable tissues along the axons and synapses
- e.g. voltage gated sodium channel
- toxin: aconitine

Aconitum napellus



https://www.chemistryworld.com/podcas ts/aconitine/1017356.article

LD for humans: 0,028mg/kg orally  $\rightarrow$  2,24mg for a 80kg person





http://www.bioinfo.org.cn/book/biochemistry/chapt22/bio7.htm






- specialized proteins that carry ions or molecules across the cell membrane
- transport may be passive or active
- e.g. Na<sup>+</sup>/K<sup>+</sup>-ATPase
- drug: cardiac glycoside











# Thank you for your attention !